Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Psyence Biomedical Ltd 주요 수익원은 Banking and Related Activities이며, 최신 수익 발표에서 수익은 8,935,000입니다. 지역별로는 United States이 Psyence Biomedical Ltd의 주요 시장이며, 수익은 8,935,000입니다.
Psyence Biomedical Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 Psyence Biomedical Ltd의 순손실은 $0입니다.